StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)

StockNews.com initiated coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research report issued on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Performance

PIRS opened at $13.60 on Friday. The company has a market cap of $17.95 million, a price-to-earnings ratio of -1.12 and a beta of 0.61. Pieris Pharmaceuticals has a one year low of $6.20 and a one year high of $22.32. The business’s fifty day moving average is $15.24 and its two-hundred day moving average is $15.04.

Institutional Investors Weigh In On Pieris Pharmaceuticals

An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. BML Capital Management LLC bought a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals accounts for about 0.4% of BML Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding. BML Capital Management LLC owned about 3.19% of Pieris Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.